UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
ETFis Series Trust I
(Exact name of registrant as specified in its Trust Instrument)
| Delaware | See Below |
| (State of incorporation or organization) | (I.R.S. Employer |
| | Identification No.) |
| | |
| 1540 Broadway, New York, New York | 10036 |
| (Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be so registered | | Name of each exchange on which each class is to be registered | | I.R.S. Employer Identification No. |
| Virtus LifeSci Biotech Clinical Trials ETF, shares of beneficial interest, no par value | | NYSE Arca, Inc. | | 47-1982477 |
| Virtus LifeSci Biotech Products ETF, shares of beneficial interest, no par value | | NYSE Arca, Inc. | | 47-1982570 |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. [X]
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. [ ]
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. [ ]
Securities Act registration statement or Regulation A offering statement file number to which this form relates:333-187668
Securities to be registered pursuant to Section 12 (g) of the Act:
(Title of class)
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Descriptions of Registrant’s Securities to be Registered.
A description of the shares of beneficial interest, no par value, of the Virtus LifeSci Biotech Clinical Trials ETF (formerly, BioShares Biotechnology Clinical Trials Fund) and the Virtus LifeSci Biotech Products ETF (formerly, BioShares Biotechnology Products Fund), each a series of the Registrant, to be registered hereunder is set forth in Post-Effective Amendment No. 109 to the Registrant’s Registration Statement on Form N-1A (Commission File Nos. 333-187668; 811-22819), as filed on February 28, 2017, which description is incorporated herein by reference.
Item 2. Exhibits.
1. Registrant’s Certificate of Trust is incorporated herein by reference to Exhibit (a)(1) to the Registrant’s Registration Statement on Form N-1A (Commission File Nos. 333-187668; 811-22819), as filed on April 2, 2013.
2. Registrant’s Certificate of Amendment to Certificate of Trust is incorporated herein by reference to Exhibit (a)(3) to the Registrant’s Pre-Effective Amendment No. 1 to the Registrant’s Registration Statement on Form N-1A (Commission File Nos. 333-187668; 811-22819), as filed on December 24, 2013.
3. Registrant’s Agreement and Declaration of Trust is incorporated herein by reference to Exhibit (a)(2) to the Registrant’s Registration Statement on Form N-1A (Commission File Nos. 333-187668; 811-22819), as filed on April 2, 2013.
4. Registrant’s By-Laws are incorporated herein by reference to Exhibit (b) to the Registrant’s Registration Statement on Form N-1A (Commission File Nos. 333-187668; 811-22819), as filed on April 2, 2013.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
| | ETFis Series Trust I |
| | | |
| | Date: | August 31, 2017 |
| | | |
| | By: | /s/ Brinton W. Frith |
| | Name: | Brinton W. Frith |
| | Title: | Chief Financial Officer |
